Enzymaticas CEO, Fredrik Lindberg will resign after having accepted an offer from a private pharmaceutical company that does not compete wih Enzymatica. Fredrik Lindberg will remain with Enzymatica until summer and act as CEO during the term of notice. The Board of Directors will as soon as possible initiate the recruitment for a new CEO. Fredrik has received an attractive offer which was difficult to resist. Since Fredrik assumed the role as CEO of Enzymatica in 2015, the company has evolved in an impressive way and is well positioned for a continued international expansion.